Our in vitro results recommend that EAM-2201 must be examined regarding opportunity in vivo pharmacokinetic drug–drug interactions caused by time-dependent inhibition of CYP2C8, CYP2C9, CYP2C19 and CYP3A4 routines and aggressive inhibition of UGT1A3 activity. This can be a preview of membership articles, log in via an establishment to check accessibility. https://audreyz949mcq2.blogsvila.com/profile